2330 related articles for article (PubMed ID: 31366569)
21.
Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
[TBL] [Abstract][Full Text] [Related]
22. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
23. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of 18F-FDG-PET/CT in staging cutaneous squamous cell carcinoma.
Mahajan S; Barker CA; Singh B; Pandit-Taskar N
Nucl Med Commun; 2019 Jul; 40(7):744-751. PubMed ID: 31095044
[TBL] [Abstract][Full Text] [Related]
25. [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].
Schriefer P; Hartmann M; Oechsle K; Meyer CP; Klutmann S; Fisch M; Bokemeyer C; Oing C
Urologe A; 2019 Apr; 58(4):418-423. PubMed ID: 30374517
[TBL] [Abstract][Full Text] [Related]
26. Clinical and Prognostic Role of 18F-FDG PET/CT in Pediatric Ewing Sarcoma.
Albano D; Dondi F; Schumacher RF; D'Ippolito C; Porta F; Giubbini R; Bertagna F
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e79-e86. PubMed ID: 31135716
[TBL] [Abstract][Full Text] [Related]
27.
Petrović J; Beatović S; Šobić-Šaranović D; Odalović S; Stojiljković M; Grozdic-Milojevic I; Veljkovic M; Jovanovic D; Artiko V
Hell J Nucl Med; 2022; 25(1):19-25. PubMed ID: 35388800
[TBL] [Abstract][Full Text] [Related]
28. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
29. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
[TBL] [Abstract][Full Text] [Related]
30. Multiple primary malignant tumors of upper gastrointestinal tract: a novel role of 18F-FDG PET/CT.
Sun L; Wan Y; Lin Q; Sun YH; Zhao L; Luo ZM; Wu H
World J Gastroenterol; 2010 Aug; 16(31):3964-9. PubMed ID: 20712059
[TBL] [Abstract][Full Text] [Related]
31. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
[TBL] [Abstract][Full Text] [Related]
32. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients.
Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U
Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755
[TBL] [Abstract][Full Text] [Related]
33. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of
Caspersen KB; Giannoutsou N; Gerke O; Alavi A; Høilund-Carlsen PF; Hess S
Ann Nucl Med; 2019 Mar; 33(3):184-192. PubMed ID: 30569441
[TBL] [Abstract][Full Text] [Related]
36. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
37. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
39. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
40. [
Sollini M; Trenti N; Malagoli E; Catalano M; Di Mento L; Kirienko A; Berlusconi M; Chiti A; Antunovic L
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1605-1615. PubMed ID: 31044264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]